

31 Jul 2022 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast version of Five Must-Know Things: BMS's new products meet early expectations; Eisai to shut a US unit in global R&D restructuring; Roche aims high for Vabysmo; US priority review for Biogen's ALS contender; and a chat with Gennova's CEO.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 29 July 2022, including: [Bristol Myers Squibb Company](#)'s new products meet early expectations; [Eisai Co., Ltd.](#) to shut a US unit in global R&D restructuring; [Roche Holding AG](#) aims high for Vabysmo; US priority review for [Biogen, Inc.](#)'s ALS contender; and a chat with [Gennova Biopharmaceuticals Ltd](#)'s CEO.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Bristol's New Products Meet Early Launch Expectations](#)" - Scrip, 27 Jul, 2022.)

(Also see "[Eisai To Shut Down H3 In Global R&D Restructuring](#)" - Scrip, 25 Jul, 2022.)

(Also see "[Roche Is 'Aiming For The Sky' With Vabysmo Commercial Launch](#)" - Scrip, 21 Jul, 2022.)

(Also see "[Biogen ALS Drug Granted FDA Priority Review, Triggering Aduhelm Déjà Vu](#)" - Scrip, 26 Jul, 2022.)

SCRIP

CITELINE COMMERCIAL

(Also see "[Podcast: CEO Of India's mRNA Pioneer Gennova On Cancer Vaccines, VC Interest](#)" - Scrip, 27 Jul, 2022.)

[Click here to explore this interactive content online](#) 